InTandem Capital Partners (“InTandem Capital” or the “Firm”), a healthcare services-focused private equity firm, announces that it has partnered with the founder and management team at Clinilabs (the “Company”), a global, full-service contract research organization (CRO) dedicated to providing a complete range of central nervous system (CNS) drug and device development services to the pharmaceutical, biotechnology, and medical technology industries. Since the Company’s inception in 2000, Clinilabs has established itself as a market leader in neuroscience therapeutics, focusing efforts exclusively in neurology, psychiatry, addiction, and rare CNS disorders.
Read the full article: InTandem Capital Partners Announces Strategic Investment in Clinilabs //
Source: https://www.businesswire.com/news/home/20250312405197/en/InTandem-Capital-Partners-Announces-Strategic-Investment-in-Clinilabs